Enhancing Regulatory Science for the Risk Based Quality Assessment of Complex Products (U01) - Clinical Trials Optional

Funding Opportunity RFA-FD-19-011 from the NIH Guide for Grants and Contracts. The purpose of this program is to support research activities that expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug products. We will also consider biological products relevant to CDER (e.g., monoclonal antibodies and therapeutic proteins) for this announcement.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding